New Zealand markets closed
  • NZX 50

    11,596.03
    -21.11 (-0.18%)
     
  • NZD/USD

    0.6402
    +0.0022 (+0.35%)
     
  • NZD/EUR

    0.6047
    +0.0011 (+0.19%)
     
  • ALL ORDS

    7,406.30
    +36.90 (+0.50%)
     
  • ASX 200

    7,213.20
    +37.70 (+0.53%)
     
  • OIL

    72.04
    +0.58 (+0.81%)
     
  • GOLD

    1,807.90
    +6.40 (+0.36%)
     
  • NASDAQ

    11,637.50
    +140.10 (+1.22%)
     
  • FTSE

    7,472.17
    -17.02 (-0.23%)
     
  • Dow Jones

    33,781.48
    +183.56 (+0.55%)
     
  • DAX

    14,264.56
    +3.37 (+0.02%)
     
  • Hang Seng

    19,826.96
    +376.73 (+1.94%)
     
  • NIKKEI 225

    27,901.01
    +326.58 (+1.18%)
     
  • NZD/JPY

    87.0450
    -0.0540 (-0.06%)
     

The Worldwide Assisted Reproductive Technology Industry is Expected to Reach $41.4 Billion by 2030

Company Logo
Company Logo

Global Assisted Reproductive Technology Market

Global Assisted Reproductive Technology Market
Global Assisted Reproductive Technology Market

Dublin, Oct. 05, 2022 (GLOBE NEWSWIRE) -- The "Assisted Reproductive Technology Market Size, Share & Trends Analysis Report by Type (IVF, Artificial Insemination), by End-use (Fertility Clinics & Other Facilities, Hospitals & Other Settings), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global assisted reproductive technology market size is expected to reach USD 41.4 billion by 2030, according to this report. It is expected to register a CAGR of 6.15% during the forecast period.

The growth of the market is mainly driven by the rising cases of infertility globally. In addition, the growing awareness about infertility and treatment methods available to conceive a child is expected to boost the industry growth during the forecast period. The rising adoption of Assisted Reproductive Technologies (ART) by couples and prospective parents trying for children is expected to boost the industry's growth.

Furthermore, the increasing use of technologies in ART, such as Artificial Intelligence (AI) and Machine learning (ML), for research and development is expected to improve patient outcomes. For instance, as per the article published in the National Library of Medicine, Preimplantation genetic testing for aneuploidies (PGT-A), when coupled with IVF, showed positive results in reversal of the effect of maternal age on the rates of implantation and also a decrease in miscarriage rates were shown in the study, especially for frozen transfers.

The COVID-19 pandemic adversely affected the industry owing to the cancellation and postponed procedures and a reduction of patient visits to fertility clinics. It adversely affected the mental health of the couples undergoing ART due to the cancellation of the procedures for IVF and artificial insemination.

The market is now slowly regaining to the pre-pandemic rates due to relaxation in the restrictions. Key companies operating in the market are adopting various strategies to gain higher market share, such as mergers and acquisitions. For instance, in January 2019, Ferrings Pharmaceuticals acquired the U.S. commercialization rights for the Ganirelix Acetate injection generic from Sun Pharma and expands its reproductive medicine portfolio to provide resources and services for ART.

Assisted Reproductive Technology Market Report Highlights

  • Based on the type, the IVF segment dominated the market in 2021 due to innovations in IVF including cryopreservation of excess embryos and sperm, Preimplantation Genetic Diagnosis (PGD) with the aid of chromosomal screening, and others that would not be possible without IVF

  • The artificial insemination segment is expected to witness the fastest CAGR from 2022 to 2030 due to the less invasive technique and involvement of fewer medicines than the IVF

  • Based on end-uses, the fertility clinics & other settings segment held the largest revenue share in 2021 due to factors, such as increased precision and availability of specialized treatment

  • Europe held the largest revenue share in 2021 owing to factors, such as the growing infertility cases and awareness programs for the treatment & detection of infertility

  • North America is expected to witness the fastest growth rate from 2022 to 2030 due to the initiatives taken by the government and competent authorities including the American Society for Reproductive Medicine, and Society for Assisted Reproductive Society (SART)

Key Topics Covered:

Chapter 1 Report Scope and Objectives

Chapter 2 Methodology

Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.2.1 Type
3.2.2 End-use
3.3 Regional Outlook
3.4 Competitive Insights

Chapter 4 Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.1.2 Related/Ancillary Market Outlook
4.2 Assisted Reproductive Technology Market Dynamics
4.2.1 Market Driver Analysis
4.2.1.1 Constant rise in infertility rates
4.2.1.2 Growing awareness and social acceptance of assisted reproductive technologies
4.5.1.3 Increasing number of single women and same-sex couples
4.2.2 Market Restraint Analysis
4.2.2.1 Changing government regulations
4.3 Assisted Reproductive Technology Market: Business Environment Analysis Tools
4.3.1 Porter's five forces analysis
4.3.2 PESTLE Analysis
4.3.2.1 Political & Legal
4.3.2.2 Economic & Social
4.3.2.3 Technological
4.4 Penetration & Growth Prospect Mapping
4.5 Qualitative Analysis: Impact of COVID-19 on Assisted Reproductive Technology Market

Chapter 5 Assisted Reproductive Technology Market: Type Analysis
5.1 Assisted Reproductive Technology Type Market Share Analysis, 2021 & 2030
5.2 Assisted Reproductive Technology Type Market: Segment Dashboard
5.3 Market Size & Forecasts and Trend Analyses, 2017 - 2030 for the Type Segment
5.3.1 In-Vitro Fertilization (IVF)
5.3.1.1 In-Vitro Fertilization (IVF) market, 2017 - 2030 (USD Million)
5.3.1.2 Fresh Donor
5.3.1.2.1 Fresh Donor market, 2017 - 2030 (USD Million)
5.3.1.3 Frozen Donor
5.3.1.3.1 Frozen Donor market, 2017 - 2030 (USD Million)
5.3.1.4 Fresh Non-donor
5.3.1.4.1 Fresh Non-donor market, 2017 - 2030 (USD Million)
5.3.1.5 Frozen Non-donor
5.3.1.5.1 Frozen Non-donor market, 2017 - 2030 (USD Million)
5.3.2 Artificial Insemination
5.3.2.1 Artificial insemination market, 2017 - 2030 (USD Million)
5.3.2.2 Intrauterine Insemination
5.3.2.2.1 Intrauterine insemination market, 2017 - 2030 (USD Million)
5.3.2.3 Intracervical Insemination
5.3.2.3.1 Intracervical insemination market, 2017 - 2030 (USD Million)
5.3.2.4 Intravaginal Insemination
5.3.2.4.1 Intravaginal insemination market, 2017 - 2030 (USD Million)
5.3.2.5 Intratubal Insemination
5.3.2.5.1 Intratubal insemination market, 2017 - 2030 (USD Million)

Chapter 6 Assisted Reproductive Technology Market: End-use Analysis
6.1 Assisted Reproductive Technology End-use Market Share Analysis, 2021 & 2030
6.2 Assisted Reproductive Technology End-use Market: Segment Dashboard
6.3 Market Size & Forecasts and Trend Analyses, 2017 - 2030 for the End-use Segment
6.3.1 Fertility Clinics & Other Facilities
6.3.1.1 Fertility Clinics & other facilities market, 2017 - 2030 (USD Million)
6.3.2 Hospitals & Other Settings
6.3.2.1 Hospitals & other settings market, 2017 - 2030 (USD Million)

Chapter 7 Assisted Reproductive Technology Market: Regional Analysis

Chapter 8 Competitive Analysis
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.2 Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.3 Company Market Position Analysis
8.4 Company Profiles
8.4.1 Cosmos Biomedical Ltd.
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 Microm U.K. Ltd.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 CooperSurgical Inc.
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 FUJIFILM IrvineScientific
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.5 Cryolab Ltd.
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic initiatives
8.4.6 Vitrolife AB
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic initiatives
8.4.7 European Sperm Bank
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 Bloom IVF Centre
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
8.4.9 Merck KGaA
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 Ferring B.V.
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/ozjivt

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900